There has been considerable is discussion around when IMU might list in the US. It has been stated at a recent roadshow, I believe, that they will hold for good/great news, so they gain maximum effect. That makes sense to me.
Thanks @Jov88 for your thoughtful analysis around possible deals on the 'Deal vs Share Price' thread, but I think my comments, which are not specifically about a deal, probably belong on this thread.
So, what do I think will be the NASDAQ 'trigger'? Well, its HER-vaxx, and more specifically, the nextHERIZON Interim Data Readout.
In this Phase 2 trial we are using the new higher dose of HER-Vaxx which is 100ug. IMO we are giving it a solid 'wack' at this dose. The nextHERIZON trial, as we know, is targeting patients with metastatic (when cancer spreads) HER-2+ gastric cancer (a HUGE market in Asia). HER-vaxx @ 100ug will be used in combo with chemo OR pembrolizumab (Keytruda), which is a multi-billion dollar earner.
Beyond the obvious safety and response oucomes, IMU will also be looking at duration (of response), PFS and OS (ie. survival). Positive results here, with this suitably higher dose, either with chemo or pembrolizumab, but especially pembrolizumab, may well be the trigger to launch on the NASDAQ (with or without a deal). Although, I would expect a deal to follow positive results very quickly.
Its hard to pick exactly when we will see this critical Data Readout but my guess is some time in Q3 this year. Note: We are now in Q2 so the clock is ticking!
Of course, a deal around any of our CF33 initiatives would also do it and, as we all know, that could arrive at any time. Always happy to hear other's thoughts and comments around our possible 'triggers'. This is my 'best guess'.
Once again, this is opinion only. Please seek professional advice when necessary.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)